All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2020; the latest 2025-01-24.
From the record
Foghorn Therapeutics Inc.'s filings since 2020 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2025-01-24) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+135.2% a year over 6 filed years; profitable in 0 of 6.
From the record
Foghorn Therapeutics Inc.'s 6 filed years say what it did: revenue went from $430 thousand in fiscal 2020 to $31 million in fiscal 2025, up 135.2% a year; it rose in 4 of 5 years; the deepest fall was 34% from fiscal 2023 to fiscal 2024; net income was positive in 0 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 5.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Foghorn Therapeutics Inc.'s shareholder treatment is put at 5.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 43% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
Leverage 155%: owes 155¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Foghorn Therapeutics Inc.'s shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 155 cents per dollar of assets, and net share issuance: its share count grew 14.7% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 49% of 315 in its family; net margin -240.3%.
From the record
Foghorn Therapeutics Inc.'s standing among 315 graded names in its industry family: revenue of $31 million in fiscal 2025 ranks in the bottom 49% by size; a net margin of -240.3% ranks in the bottom 44%; revenue growth of 17.1% a year over the last 3 filed years ranks in the top 40% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 49% of 315 in its family for leadership; chief executive since 2020.
From the record
Foghorn Therapeutics Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Gottschalk, Adrian (Chief Executive Officer, as filed), filing under that title since 2020-10-22, 6.1 years (top 39% of its family); the 18 officers and directors filing in the last fifteen months have been on the record a median of 4.9 years (bottom 34%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 18 people in charge now (top 47%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 45% of 273 in its family for room to expand.
From the record
Foghorn Therapeutics Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $84 million against no long-term debt tagged leaves 42.5% of its assets as net cash, top 37% of its family; cash from operations less capital spending is -278.7% of revenue (bottom 41%); research spending of 276.5% of revenue (top 38%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 29% of 306 in its family for growth drivers.
From the record
Foghorn Therapeutics Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 17.1% a year over the last three filed years against 135.2% over all 6, slowing (bottom 2% of its family); the newest year grew 36.8% (top 30%); research spending grew -6.8% a year (bottom 37%); capital spending grew -65.4% a year (bottom 10%) (its annual reports). Foghorn Therapeutics Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 32% of 233 in its family for expectations against reality.
From the record
Foghorn Therapeutics Inc.'s newest year against its own record: revenue of $31 million in fiscal 2025 came in 26.1% above the $25 million its prior three years' pace pointed to (top 24% of its family); net income of $74 million against a prior three-year average of $98 million (top 44%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 27%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made